Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01256983
Other study ID # SleepTx-1
Secondary ID
Status Completed
Phase Phase 0
First received December 8, 2010
Last updated January 29, 2014
Start date October 2010
Est. completion date July 2013

Study information

Verified date January 2014
Source University of Basel
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

Sleep-wake dysregulation is a disturbance in the roughly 24-hour cycle of the circadian rhythm. Well known disorders presenting a sleep-wake dysregulation are seasonal affective disorder, jet lag and shift work. These people experience a serious mood change when the seasons change. When the day-night rhythm is desynchronized, they have sleep disturbances, little energy, and often feel depressed. An established intervention to treat this disorder is bright light therapy. Light therapy is used for affective disorders for shift workers, jet lag symptomatology and for advancing or delaying desynchronized rhythms.Two proxy measures for sleep-wake dysregulation are sleep quality and daytime sleepiness. It is known from cross sectional studies that renal transplant (RTx) recipients have a prevalence between 30% to 62% of poor sleep quality measured by self report; a prevalence of impaired daytime functioning of 34% 12 and a prevalence of depressive symptomatology of 20% to 22%. Sleep-wake dysregulation in other chronically ill population are a risk factor for morbidity and mortality.

RTx nurses in the follow-up care are in the frontline for recipient's symptoms respectively problems. The psychosocial variables that should be addressed, having an association with morbidity and mortality are sleep, daytime functioning, adherence to immunosuppressive medication, exercise, smoking and depressive symptomatology.

In the following research project we will address the following gaps: the fact that nature of sleep disturbances in RTx recipients has never been assessed, that there is no prevalence available on sleep-wake dysregulation and that there is no data on bright light therapy intervention in RTx recipients.

Hypothesis: Renal transplant recipients having a sleep wake disregulation will have an improved sleep quality and less daytime sleepiness after 21 days of light therapy.


Description:

This research project has three phases:

The first phase is a cross sectional survey including all patients transplanted in Basel, Bern and in Zurich speaking German and transplanted at least 6 months ago. Renal transplant recipients having poor sleep quality and / or daytime sleepiness as result of this first phase will be asked to participate in phase two. Phase two is an sleep assessment, resulting in a presumed sleep diagnosis.

Renal transplant recipients having a sleep wake dysregulation, assessed in phase two, will be asked to participate in phase three. Phase three is a pilot randomized controlled trial to compare the sustained impact of bright light therapy on sleep-wake regulation.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- For phase 1: all renal transplant recipients transplanted at the University Hospital Basel, Bern and Zurich, speaking German and having an actual address on the follow-up list of the ambulatory center list.

- Renal transplant recipients who have poor Sleep quality and /or daytime sleepiness (phase 1: Cross sectional survey study) and had a Sleep assessment (phase 2: Cross sectional diagnostic interview study)

- Renal transplant recipients who participated in Phase 1 and 2 that were diagnosed with sleep wake dysregulation

- Renal transplant recipients with signed written informed consent.

Exclusion Criteria:

- RTx recipients, who participated in phase 2, will be excluded in the study if

- they were diagnosed with sleep disorders as parasomnia, breathing disorders or movement disorders.

- they were diagnosed with alcohol or substance abuse

- they are blind or suffer from a severe vision impairment (cataract), which possibly limits the effect of the light intervention and patients taking photosensitive medications

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Bright Light Therapy
10000 Lux for 30 Minutes according to sleep wake rhythm
Wait-list intervention
10000 Lux for 30 Minutes according to sleep wake rhythm

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
University of Basel University Hospital Inselspital, Berne, University Hospital, Basel, Switzerland, University Hospital, Zürich

Outcome

Type Measure Description Time frame Safety issue
Primary Bedtime The mean "bedtime" assessed by actimetry of each 3 week period (day 21, 42, 63 ) was used as outcome to be compared with the control group.
Bedtime is expressed in time (hours and minutes)
Mean Bedtimes over 21 days for each period No
See also
  Status Clinical Trial Phase
Completed NCT02188498 - Electrocardiography Data Analysis in Sleep Disorders
Completed NCT00990106 - Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD) N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00163670 - The Impact of Sleep Disorders on Motor Vehicle Accidents N/A
Completed NCT00256685 - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Phase 3
Completed NCT00203827 - Pediatric Sleep Questionnaire: Use for Collection of Clinical Data N/A
Completed NCT00174174 - Provigil (Modafinil) Study by Taiwan Biotech Co. N/A
Terminated NCT00750919 - Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) Phase 3
Completed NCT02939586 - The Effect of Haemodialysis in Sleep Apnoea N/A
Completed NCT03075241 - Z-Drugs for Sleep Disorders in Alzheimer's Disease Phase 3
Completed NCT03055156 - Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms N/A
Completed NCT02585609 - Sleep Quality in Patients With Advanced Cancer N/A
Completed NCT01929447 - Evaluation of WP200 With the Unified Probe (WP200U) N/A
Completed NCT02156128 - Subjective Memory Complaints, Objective Memory Performance and Cognitive Training N/A
Completed NCT01906866 - Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities Phase 3
Completed NCT01528462 - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed NCT01220401 - Efficacy of a Brief Nightmare Treatment for Veterans N/A
Not yet recruiting NCT00749814 - Sleep Disturbances in Hospitalized Children Phase 4
Completed NCT00518986 - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Phase 4
Completed NCT00397930 - Yoga in Treating Sleep Disturbance in Cancer Survivors Phase 2